Edition:
United Kingdom

PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

43.15USD
4:41pm BST
Change (% chg)

$-0.28 (-0.64%)
Prev Close
$43.43
Open
$43.90
Day's High
$43.90
Day's Low
$42.90
Volume
56,706
Avg. Vol
338,919
52-wk High
$52.95
52-wk Low
$14.57

Chart for

About

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $812.47
Shares Outstanding(Mil.): 41.39
Dividend: --
Yield (%): --

Financials

  PTCT.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -3.10 -- --
ROI: -37.56 1.78 14.61
ROE: -64.70 3.28 16.33

BUZZ-PTC Therapeutics: Jumps on deal to buy Agilis Biotherapeutics

** Drug developer's shares up nearly 9 pct at $40.07 in early trading on Friday

20 Jul 2018

Roche SMA drug shines in study as costly new therapies advance

ZURICH A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.

18 Jun 2018

Roche SMA drug shines in study as costly new therapies advance

ZURICH, June 18 A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.

18 Jun 2018

BRIEF-PTC Therapeutics Reports Q1 Loss Per Share $0.46

* PTC THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

09 May 2018

BRIEF-PTC Therapeutics announces presentation of preliminary data from Part 1,dose finding portion, of ongoing FIREFISH clinical trial

* PRELIMINARY CLINICAL DATA FROM FIREFISH TRIAL IN TYPE 1 SMA PATIENTS PRESENTED AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING

25 Apr 2018

BRIEF-PTC Therapeutics Prices Public Offering Of Common Stock At $27.04 Per Share​

* PTC THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

29 Mar 2018

BRIEF-PTC Therapeutics Announces Proposed Public Offering Of Common Stock

* PTC THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

27 Mar 2018

BRIEF-Ptc Therapeutics Says ‍Firefish Study Of RG7916 In Type 1 Spinal Muscular Atrophy Patients Transitioned Into Pivotal Phase With Dosing First Patient​

* PTC THERAPEUTICS INC - ‍FIREFISH STUDY OF RG7916 IN TYPE 1 SPINAL MUSCULAR ATROPHY PATIENTS TRANSITIONED INTO PIVOTAL PHASE WITH DOSING FIRST PATIENT​ Source text for Eikon: Further company coverage:

15 Mar 2018

BRIEF-PTC Therapeutics Q4 Revenue $78.0 Million

* ‍TOTAL REVENUES FOR Q4 OF 2017 WERE $78.0 MILLION COMPARED TO $25.2 MILLION IN Q4 OF 2016​

06 Mar 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $41.28 +0.12
Merck & Co., Inc. (MRK.N) $68.57 +1.20
Bayer AG (BAYGn.DE) €77.05 -3.74
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates